Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPIRE: SBRT + Botensilimab + Balstilimab in Metastatic Pancreatic Cancer
NCT06843551Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Aug 2030
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of botensilimab, balstilimab in pancreatic ductal adenocarcinoma (PDAC). Started Jun 2025; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06843551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843551.